Anagram Therapeutics
- Health & Biotech
- Natick, MA, US
- Founded 2023
- Private
- anagramtx.com
Develops an oral enzyme replacement therapy for exocrine pancreatic insufficiency in cystic fibrosis, pancreatic cancer and related disorders.
$250MEquity raised in 2025–20262025 — · 2026 $250M · 1 equity round
$250MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 2 sources
Earlier rounds not yet sourced. Anagram Therapeutics was founded in 2023 and raised before 7 May 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- $250M investmentAmount$250MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 1
- Blackstone1
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Shield AIDefense · $4.2B in 2025–2026Shared: BlackstoneCyeraCyber · $1.9B in 2025–2026Shared: BlackstoneQuantum SystemsDefense · $1.6B in 2025–2026Shared: BlackstoneVoltaGridEnergy · $775M in 2025–2026Shared: BlackstoneNeysaAI Infra · $600M in 2025–2026Shared: BlackstoneAnthropicAI Labs · $113B in 2025–2026Shared: Blackstone
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Anagram Therapeutics and its logo are trademarks of their owners, used here for identification only.
